July 7 (Reuters) - Eisai Co Ltd and Biogen Inc's Leqembi emerged as the first Alzheimer's treatment to win the U.S. Food and Drug Administration's standard approval on Thursday, a milestone in drug development for a disease that has seen multiple failures in the past. The following is a list of companies that are currently developing treatments that aim to modify the memory-robbing disease: Company Drug or Stage of Mechanism Therapy development & indication Eli Lilly donanemab Designed to and Co Late-stage trial target toxic for early protein plaque Alzheimer’s in the brain known as beta-amyloid and remove brain plaques to slow cognitive decline BioVie Inc NE3107 An oral small Late-stage trial molecule that for mild to aims to inhibit moderate neuroinflammati Alzheimer’s on and insulin resistance AB Science masitinib An oral SA Late-stage study tyrosine kinase for inhibitor that mild-to-moderate targets immune Alzheimer’s cells responsible for neuroinflammati on Annovis buntanetap An Bio Inc Mid-to-late-stage orally-administ trial for moderate ered small Alzheimer's molecule inhibitor of several neurotoxic proteins Cognition CT1812 Oral drug Therapeuti Mid-stage trial designed to cs Inc for bind to a mild-to-moderate specific Alzheimer’s receptor in brain cells, which mediates the attachment of beta-amyloid Coya COYA 301 Designed to Therapeuti Mid-stage trial inhibit cs Inc for molecules mild-to-moderate responsible for Alzheimer’s neuroinflammati on and improve cognitive function Actinogen xanamem Blocks Medical Mid-stage trial production of a Limited for mild-moderate hormone linked Alzheimer's to stress called cortisol inside brain cells and is associated with cognitive impairment AC Immune ACI-24.060 Early- An SA -to-mid stage antibody-based trial for immunotherapy Alzheimer’s vaccine designed to target beta amyloid plaques Biogen Inc BIIB080 An antisense Mid-stage trial oligonucleotide for early-stage therapy Alzheimer’s directed against "tau" proteins Longeveron lomecel-B A cell therapy Inc Mid-stage trial designed to for mild stimulate Alzheimer’s neuroregenerati on and prevent disease progression (Reporting by Pratik Jain and Mariam Sunny in Bengaluru; Editing by Maju Samuel)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
231.7 USD | -0.92% | +2.78% | -10.46% |
Jun. 13 | REGENXBIO Inc. Announces Chief Executive Officer Changes | CI |
Jun. 12 | Biogen executive plays down looming competition for its Alzheimer's drug | RE |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
6,256 JPY | -2.40% | -7.57% | 11.38B | ||
2,747 PTS | +0.54% | -0.31% | - | ||
878.4 USD | -0.55% | +3.35% | 791B | ||
231.7 USD | -0.92% | +2.78% | 33.73B | ||
7.2 USD | -7.46% | +0.14% | 110M | ||
5.85 USD | -2.66% | -5.19% | 65.35M | ||
4.26 USD | -9.94% | -10.69% | 400M | ||
3.19 USD | +18.59% | +206.73% | 20.25M | ||
2.17 USD | -1.36% | +11.28% | 86.93M | ||
1.1 EUR | -7.25% | -11.00% | 69.58M | ||
0.4601 USD | -5.37% | +6.75% | 28.05M | ||
0.032 AUD | +6.67% | -5.88% | 56.75M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.46% | 33.73B | |
+0.85% | 92.38B | |
-3.03% | 37.9B | |
+74.71% | 27.98B | |
-13.39% | 15.86B | |
-1.08% | 13.97B | |
-11.15% | 11.67B | |
+169.04% | 10.17B | |
-50.19% | 10.04B | |
+1.12% | 8.71B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Companies in Alzheimer's race after US nod for Eisai/Biogen drug